Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TYMP | P19971 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15302729 | 0.87 | CHRM1 (0.41) | CHRM1LMNAALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL1712993 | 0.81 | CHRM1 (0.37) | CHRM1POLBSMN1; SMN2 | |
| SCHEMBL1063255 | 0.81 | LMNA (0.36) | CYP2C19HIF1ALMNAALDH1A1TYMP | |
| SCHEMBL11967754 | 0.81 | CHRM1 (0.37) | CHRM1ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL12323568 | 0.79 | LMNA (0.34) | CYP2C19HIF1ALMNAALDH1A1TYMP | |
| SCHEMBL26535302 | 0.78 | CHRM1 (0.38) | CHRM1 | |
| SCHEMBL10305069 | 0.77 | LMNA (0.33) | LMNAALDH1A1TYMP | |
| SCHEMBL20934754 | 0.77 | LMNA (0.33) | LMNAALDH1A1TYMP | |
| SCHEMBL17703490 | 0.77 | LMNA (0.33) | LMNAALDH1A1TYMP | |
| SCHEMBL16750127 | 0.77 | LMNA (0.33) | LMNAALDH1A1TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4444300-A2 | INHIBITORS OF MENIN-MLL INTERACTION | Bala Therapeutics, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| US-20230321284-A1 | COMPOUND, CONTRAST AGENT, AND METHOD FOR PRODUCING COMPOUND | ST. MARIANNA UNIVERSITY SCHOOL OF MEDICINE (JP) | 2023-10-12 | — | — | US | disclosed |
| US-20230321284-A1 | COMPOUND, CONTRAST AGENT, AND METHOD FOR PRODUCING COMPOUND | ST. MARIANNA UNIVERSITY SCHOOL OF MEDICINE (JP) | 2023-10-12 | — | — | US | disclosed |
| WO-2023107696-A2 | INHIBITORS OF MENIN-MLL INTERACTION | BALA THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20200308109-A1 | FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2020-10-01 | — | — | US | disclosed |
| US-20190177271-A1 | FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2019-06-13 | — | — | US | disclosed |
| WO-2019034688-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2019-02-21 | — | — | WO | disclosed |
| EP-2863916-B1 | SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK SHARP & DOHME (US) | 2018-07-18 | — | — | EP | disclosed |
| US-9376418-B2 | Substituted pyridine spleen tyrosine kinase (SYK) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20150329491-A1 | FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2015-11-19 | — | — | US | disclosed |
| US-20150148327-A1 | SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK CANADA INC. (CA) | 2015-05-28 | — | — | US | disclosed |
| US-8871934-B2 | Fluorene compound and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2014-10-28 | — | — | US | disclosed |
| US-20130274240-A1 | FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (US) | 2013-10-17 | — | — | US | disclosed |
| US-8343994-B2 | Fluorene compound and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2013-01-01 | — | — | US | disclosed |
| EP-2345629-A1 | FLUORENE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | Japan Tobacco, Inc. (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-20100240634-A1 | Fluorene Compound and Pharmaceutical Use Thereof | JAPAN TOBACCO INC. (JP) | 2010-09-23 | — | — | US | disclosed |
| US-7745641-B2 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-06-29 | — | — | US | disclosed |
| US-7745641-B2 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-06-29 | — | — | US | disclosed |
| US-20090054407-A1 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| US-20090054407-A1 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329491-A1 | FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF | FH, PCK2, PC | CYP2C19 1307/4885HIF1A 560/4885CHRM1 4381/4885 |
| US-20100240634-A1 | Fluorene Compound and Pharmaceutical Use Thereof | FH, PCK2, PC | CYP2C19 1307/4885HIF1A 560/4885CHRM1 4381/4885 |
| US-20090054407-A1 | Nitrogen-containing heterocyclic compound | NR4A1, NR5A2, PRMT8 | CYP2C19 531/4885HIF1A 2615/4885CHRM1 27/4885 |
| US-20130274240-A1 | FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF | FH, PCK2, PC | CYP2C19 1307/4885HIF1A 560/4885CHRM1 4381/4885 |
| US-20190177271-A1 | FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF | FH, PCK2, PC | CYP2C19 1307/4885HIF1A 560/4885CHRM1 4381/4885 |
| US-20200308109-A1 | FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF | FH, PCK2, PC | CYP2C19 1307/4885HIF1A 560/4885CHRM1 4381/4885 |
| US-20150148327-A1 | SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS | SYK, BTK, LYN | CYP2C19 964/4885HIF1A 3348/4885CHRM1 1284/4885 |
| US-20230321284-A1 | COMPOUND, CONTRAST AGENT, AND METHOD FOR PRODUCING COMPOUND | RXFP1, AVPR2, RXFP3 | CYP2C19 2707/4885HIF1A 568/4885CHRM1 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.